Atai Life Sciences N.V. (ATAI)

DE — Healthcare Sector
Peers: CMPS  CYBN  GHRS  MNMD 

Automate Your Wheel Strategy on ATAI

With Tiblio's Option Bot, you can configure your own wheel strategy including ATAI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ATAI
  • Rev/Share 0.0117
  • Book/Share 0.7322
  • PB 6.0718
  • Debt/Equity 0.0641
  • CurrentRatio 4.0193
  • ROIC -0.578

 

  • MktCap 950863660.0
  • FreeCF/Share -0.411
  • PFCF -11.7699
  • PE -7.3092
  • Debt/Assets 0.0487
  • DivYield 0
  • ROE -0.8562

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ATAI Oppenheimer -- Outperform -- $14 July 29, 2025

News

atai Life Sciences Announces Proposed Public Offering of Common Shares
ATAI
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of $55,000,000 of its common shares. atai expects to grant the underwriter a 30-day option to purchase up to an additional $8,250,000 of common shares. All common shares to be sold in the offering will be sold by atai.

Read More
image for news atai Life Sciences Announces Proposed Public Offering of Common Shares

About Atai Life Sciences N.V. (ATAI)

  • IPO Date 2021-06-18
  • Website https://www.atai.life
  • Industry Biotechnology
  • CEO Srinivas G. Rao
  • Employees 54
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.